计划状态
活跃，非招募阶段
第 1 阶段允许先接受免疫治疗
没有CRC 指导的试验
没有药物
5-FU + Cisplatin, Evorpacept (ALX148), Pembrolizumab, Ramucirumab + Paclitaxel, Rituximab, Trastuzumab标签
MSS/ MMRp评论
Phase 1 protocol will have 2 parts: a single agent dose escalation phase (Part 1) and a combination therapy phase (Part 2), with Pembrolizumab, Trastuzumab, or Rituximab .
Part 2 will include an initial dose escalation portion followed by a dose expansion portion.
CD47/SIRPa-blocking agent ALX148
Potential phagocytosis-inducing, immunostimulating and antineoplastic activities. Upon administration, ALX148 binds to CD47 expressed on tumor cells and prevents the interaction of CD47 with its ligand SIRPa, a protein expressed on phagocytic cells. This prevents CD47/SIRPa-mediated signaling and abrogates the CD47/SIRPa-mediated inhibition of phagocytosis. This induces pro-phagocytic signaling mediated by the binding of the pro-phagocytic signaling protein calreticulin (CRT), which is specifically expressed on the surface of tumor cells, to low-density lipoprotein (LDL) receptor-related protein (LRP), expressed on macrophages. This results in macrophage activation and the specific phagocytosis of tumor cells. In addition, blocking CD47 signaling activates both an anti-tumor cytotoxic T-lymphocyte (CTL) immune response and T-cell-mediated killing of CD47-expressing tumor cells. CD47, also called integrin-associated protein (IAP), is a tumor-associated antigen (TAA) expressed on normal, healthy hematopoietic stem cells (HSC) and overexpressed on the surface of a variety of cancer cells. Expression of CD47, and its interaction with SIRPa, leads to the inhibition of macrophage activation and protects cancer cells from phagocytosis, which allows cancer cells to proliferate.
| 地点 | 位置状态 |
|---|---|
| 美国 | |
|
University of Colorado Denver 科罗拉多州丹佛 80045 |
活跃，非招募 |
|
耶鲁大学 康涅狄格州纽黑文 06520 |
活跃，非招募 |
|
麻省总医院 马萨诸塞州波士顿 02114 |
活跃，非招募 |
|
达纳法伯癌症研究所 马萨诸塞州波士顿 02215 |
活跃，非招募 |
|
START-Midwest Grand Rapids, Michigan 49503 |
活跃，非招募 |
|
Seattle Cancer Care Alliance 华盛顿州西雅图 98109 |
活跃，非招募 |
| 大韩民国 | |
|
Seoul National University Bundang Hospital Seongnam |
活跃，非招募 |
|
三星医疗中心 Seoul |
活跃，非招募 |
|
首尔大学医院 Seoul |
活跃，非招募 |
|
Severance Hospital, Yonsei University Seoul |
活跃，非招募 |
纳入标准
纳入标准
Histological or cytological diagnosis of advanced/metastatic solid tumor malignancy; or relapsed or refractory Non-Hodgkin lymphoma for whom no standard therapy is available..
Adequate Bone Marrow Function.
Adequate Renal & Liver Function.
Adequate Performance Status
排除标准
排除标准：
Patients with known symptomatic CNS metastases or lepotomeningeal disease requiring steroids.
Previous high-dose chemotherapy requiring allogenic stem cell rescue.
Prior treatment with a CD47 or signal regulatory protein (SIRP) alpha targeting agent.
